Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H27N9O6S |
Molar mass | 605.63 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]